Combination of validated progressive multifocal leukoencephalopathy (PML) risk factors and resulting risks for natalizumab-associated PML
Reference:
- Biogen Idec. Biogen Idec MedInfo. Available at: medinfo.biogenidec.com (Accessed on June 4, 2016).
From: Schwab N, Schneider-Hohendorf T, Melzer N, et al. Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. Neurology 2017; 88:1197. DOI:
10.1212/WNL.0000000000003739. Copyright © 2017 American Academy of Neurology. Reproduced with permission from Lippincott Williams & Wilkins. Unauthorized reproduction of this material is prohibited.